Alexander Fosså

Author information from the last article

Alexander Fosså (f. 1968) er dr.med. og overlege ved Lymfomseksjonen. Forfatteren har bidratt med analyse og tolking og utarbeiding og/eller kritisk revisjon av selve manuskriptet og har godkjent endelig versjon.

Forfatter har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter.

Avdeling for kreftbehandling

Oslo universitetssykehus

Articles by Alexander Fosså

High-dose therapy with autologous stem cell support for lymphoma in Norway 1987 – 2008

Knut Bjøro Smeland,
Cecilie E. Kiserud,
Grete F. Lauritzsen,
Anne Kirsti Blystad,
Unn Merete Fagerli,
Øystein Fluge,
Alexander Fosså,
Jens Hammerstrøm,
Arne Kolstad,
Jon Håvard Loge,
Martin Maisenhølder,
Bjørn Østenstad,
Stein Kvaløy,
Harald Holte

03.09.2013: High-dose therapy with autologous stem cell support (HDT) is a very intensive, highly specialised and resource-intensive therapy. It has been a treatment option for lymphomas for 25 years. Based on results from prospective studies, it has progressed from being an experimental form of treatment to...

High-dose therapy with autologous stem cell support for lymphoma – from experimental to standard treatment

Knut Bjøro Smeland,
Cecilie E. Kiserud,
Grete F. Lauritzsen,
Alexander Fosså,
Jens Hammerstrøm,
Vidar Jetne,
Arne Kolstad,
Gunnar Kvalheim,
Jon Håvard Loge,
Turid Løkeland,
Jon Magnus Tangen,
Harald Holte,
Stein Kvaløy

03.09.2013: High-dose therapy with autologous stem cell support (HDT) for lymphomas has been given in Norway since 1987. The therapy consists of intensive chemotherapy and/or total body irradiation in such high doses that it entails a life-threatening loss of healthy haematopoietic stem cells in the bone marrow...